Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28559447 | 0.78 | HTT (0.48) | MEN1KMT2AMAPTTP53 | |
| SCHEMBL23569180 | 0.76 | L3MBTL1 (0.33) | L3MBTL1MEN1KMT2AMAPTTP53 | |
| SCHEMBL20680915 | 0.75 | MLYCD (0.34) | — | |
| SCHEMBL20698974 | 0.75 | — | — | |
| SCHEMBL20681132 | 0.74 | GAA (0.31) | GAA | |
| SCHEMBL25033769 | 0.74 | EDNRB (0.51) | MAPTPFKFB3 | |
| SCHEMBL25034034 | 0.74 | ALDH1A1 (0.35) | L3MBTL1MEN1POLBKMT2AMAPT | |
| SCHEMBL25794370 | 0.74 | NLRP3 (0.42) | L3MBTL1 | |
| SCHEMBL23386023 | 0.72 | PTGS2 (0.31) | — | |
| SCHEMBL23386022 | 0.72 | PTGS2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976054-B2 | Amide derivative and preparation method therefore and use thereof in medicine | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-05-07 | — | — | US | disclosed |
| CN-117105890-A | Amide derivative, preparation method thereof and application thereof in medicine | 成都百裕制药股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20220411392-A1 | Amide Derivative And Preparation Method Therefore And Use Thereof In Medicine | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| EP-4059930-A1 | AMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2022-09-21 | — | — | EP | disclosed |
| CN-112851607-A | Amide derivative, preparation method and medical application thereof | 成都百裕制药股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| WO-2021093820-A1 | AMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-05-20 | — | — | WO | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976054-B2 | Amide derivative and preparation method therefore and use thereof in medicine | NLRP3, NLRP1, PYCARD | L3MBTL1 4301/4885MEN1 1965/4885POLB 4452/4885 |
| US-20220411392-A1 | Amide Derivative And Preparation Method Therefore And Use Thereof In Medicine | NLRP3, NLRP1, PYCARD | L3MBTL1 4301/4885MEN1 1965/4885POLB 4452/4885 |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | L3MBTL1 4814/4885MEN1 3797/4885POLB 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.